Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Conmed (CNMD) EBIT Margin (2016 - 2025)

Conmed's EBIT Margin history spans 16 years, with the latest figure at 9.81% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 536.0% year-over-year to 9.81%; the TTM value through Dec 2025 reached 7.46%, down 786.0%, while the annual FY2025 figure was 7.46%, 786.0% down from the prior year.
  • EBIT Margin reached 9.81% in Q4 2025 per CNMD's latest filing, up from 3.52% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 20.75% in Q3 2024 to a low of 0.44% in Q4 2022.
  • Average EBIT Margin over 5 years is 9.92%, with a median of 9.88% recorded in 2023.
  • Peak YoY movement for EBIT Margin: soared 2354bps in 2021, then tumbled -1723bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 13.58% in 2021, then tumbled by -103bps to 0.44% in 2022, then soared by 3616bps to 15.35% in 2023, then fell by -1bps to 15.18% in 2024, then tumbled by -35bps to 9.81% in 2025.
  • Per Business Quant, the three most recent readings for CNMD's EBIT Margin are 9.81% (Q4 2025), 3.52% (Q3 2025), and 11.15% (Q2 2025).